Liam Sharkey

Oct 23, 2024 | nature.com | Adrianna M Turner |Ian R. Monk |Danielle Ingle |Stephanie Portelli |Torsten Seemann |Liam Sharkey | +7 more

AbstractMultidrug-resistant bacterial pathogens like vancomycin-resistant Enterococcus faecium (VREfm) are a critical threat to human health1. Daptomycin is a last-resort antibiotic for VREfm infections with a novel mode of action2, but for which resistance has been widely reported but is unexplained. Here we show that rifaximin, an unrelated antibiotic used prophylactically to prevent hepatic encephalopathy in patients with liver disease3, causes cross-resistance to daptomycin in VREfm.